Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: Implications for sodium iodide symporter gene therapy

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4915-

  Hingorani, Mohan ^a   White, Christine L ^a   Zaidi, Shane ^a   Merron, Andrew ^b   Peerlinck, Inge ^b   Gore, Martin E ^c   Nutting, Christopher M ^c   Pandha, Hardev S ^d   Melcher, Alan A ^e   Vile, Richard G ^f   Vassaux, Georges ^g   Harrington, Kevin J ^a,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f MAYO CLINIC   (United States)

^g HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CD51 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GREEN FLUORESCENT PROTEIN; IODINE 131; LUCIFERASE; SODIUM IODIDE SYMPORTER; TELOMERASE REVERSE TRANSCRIPTASE; COTRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENETIC TRANSDUCTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE; RECEPTOR GENE; SOLID TUMOR; TRANSGENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; CANCER TRANSPLANTATION; GENE THERAPY; GENE VECTOR; GENETICS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; NUDE MOUSE; RADIOTHERAPY; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; RADIOTHERAPY; SYMPORTERS;

EID: 51049090383     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4049     Document Type: Article

References (27)

1. Levy O, Carrasco N. Structure and function of the thyroid iodide transporter and its implications for thyroid disease. Curr Opin Endocrinol Diabetes 1997;4: 364-70.
2. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Clinical review 132: the sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001;86:3327-35.
3. Park HJ, Kim JY, Park KY, Gong G, Hong SJ. Ahn IM. Expression of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid 2000;10:211-7.
4. Cho J Y Xing S, Liu X, et al. Expression and activity of human Na+/I-symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther 2000;7: 740-9.
5. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC, Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000;60: 6526-30.
6. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001;8:1524-31.
7. Groot-Wassink T, Aboagye EO, Glaser M, et al. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 2002;13:1723-35.
8. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)- PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003;63:7840-4.
9. Gaut AW, Niu G, Krager KJ, Graham MM, Trask DK, Domann FE. Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodiumiodide symporter (NIS). Head Neck 2004;26:265-71.
10. Scholz IV, Cengic N, Baker CH. et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 2005; 12:272-80.
11. Kassis Al, Adelstein SJ. Radiobiological principles in radionuclide therapy. J Nucl Med 2005;46:4-12S.
12. Boyd M, Mairs SC, Stevenson K, et al. Transfectant mosaic spheroids: a new model for evaluation of tumor cell killing in targeted radiotherapy and experimental gene therapy. J Gene Med 2002;4: 567-76.
13. Boyd M, Ross SC, Dorrens J, et al. Radiationinduced biological bystander effect elicited in vitro by targeted radiopharmaceuticals labelled with α-, β-, and auger electron-emitting radionuclides. J Nucl Med 2006;47:1007-15.
14. Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis Al, Bystander effects produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci U S A 2002; 99:13765-70.
15. Little JB, Azzam El, DeToledo SM, Nagasawa H. Bystander effects: intercellular transmission of radiation damage signals. Radiat Prot Dosimetry 2002;99: 159-62.
16. Hingorani M, White CL, Agrawal VK. Vidal L, Melcher A, Harrington KJ. Combining radiation and cancer gene therapy. A potential marriage of physical and biological targeting? Curr Cancer Drug Targ 2007; 7:191-211.
17. Williams JR, Zhang Y-G, Dillehay LE. Sensitization processes in human tumor cells during protracted radiation: possible exploitation in the clinic. Int J Radiat Oncol Biol Phys1992;24:699-704.
18. Qian J, Yang J, Dragovic AF. et al. Ionizing radiationinduced adenovirus infection is mediated by dynamin 2. Cancer Res 2005;65:5493-7.
19. Zacal NJ. Francis MA, Rainbow AJ. Enhanced expression from the human cytomegalovirus immediate-early promoter in a non-replicating adenovirus encoded reporter gene following cellular exposure to chemical DNA damaging agents Biochem Biophys Res Commun 2005;332:441-9
20. Harrington KJ, Nutting CM. Interactions between ionising radiation and drugs in head and neck cancer-how can we maximize the therapeutic index? Curr Opin Investig Drugs 2002;3:807-11
21. Clark C, Mubata CD, Bidmead AM, Harrington KJ. Nutting CM. Intensity modulated radiotherapy (IMRT) improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx Radiother Oncol 2004; 70:189-98.
22. Guerrero Urbano MT, Clark C, Hansen V. et al Intensity modulated radiotherapy (IMRT) in locally advanced non-anaplastic thyroid cancer early results of a phase I study. Radiother Oncol 2007;85:58-63
23. Guerrero Urbano MT, Clark CH, Hansen VN, et al Neoadjuvant chemotherapy followed by concomitant chemotherapy and intensity modulated radiotherapy (IMRT) in locally advanced laryngeal and hypopharyngeal cancer: a phase 1 dose escalation study Radiother Oncol 2007;85:36-41.
24. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy Int J Rad Oncol Biol Phys 1990;18:1261-9.
25. Price P, Hoskin PJ. Easton D, Austin D. Palmer S. Yarnold JR. Low dose single fraction radiotherapy in the treatment of metastatic bone pain a pilot study Radiother Oncol 1988;12:297-300
26. Hoskin PJ, Price P. Easton D, et al A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain Radiother Oncol 1992;23:74-8.
27. Bezjak A. Dixon P. Brundage M, et al Randomised phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15) Int J Radiat Oncol Biol Phys 2002; 54:719-28.